Submissions for variant NM_000257.4(MYH7):c.4916C>T (p.Ala1639Val)

gnomAD frequency: 0.00002  dbSNP: rs1195157116

Total submissions: 8

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
GeneDx	RCV000497471	SCV000589935	uncertain significance	not provided	2024-10-02	criteria provided, single submitter	clinical testing	Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis indicates that this missense variant does not alter protein structure/function; Has not been previously reported as pathogenic or benign in association with MYH7-related disorders to our knowledge; This variant is associated with the following publications: (PMID: 34542152)
Color Diagnostics, LLC DBA Color Health	RCV001183002	SCV001348647	uncertain significance	Cardiomyopathy	2023-01-27	criteria provided, single submitter	clinical testing	This missense variant replaces alanine with valine at codon 1639 of the MYH7 protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has not been reported in individuals affected with MYH7-related disorders in the literature. This variant has been identified in 1/31384 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.
Molecular Diagnostic Laboratory for Inherited Cardiovascular Disease, Montreal Heart Institute	RCV000497471	SCV001433095	uncertain significance	not provided	2019-07-04	criteria provided, single submitter	clinical testing
Labcorp Genetics (formerly Invitae), Labcorp	RCV001347665	SCV001541935	uncertain significance	Hypertrophic cardiomyopathy	2023-12-18	criteria provided, single submitter	clinical testing	This sequence change replaces alanine, which is neutral and non-polar, with valine, which is neutral and non-polar, at codon 1639 of the MYH7 protein (p.Ala1639Val). This variant is present in population databases (no rsID available, gnomAD no frequency). This variant has not been reported in the literature in individuals affected with MYH7-related conditions. ClinVar contains an entry for this variant (Variation ID: 432229). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt MYH7 protein function with a positive predictive value of 95%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Fulgent Genetics, Fulgent Genetics	RCV002481582	SCV002787968	uncertain significance	Hypertrophic cardiomyopathy 1; Myopathy, myosin storage, autosomal recessive; Myosin storage myopathy; Congenital myopathy with fiber type disproportion; Dilated cardiomyopathy 1S; MYH7-related skeletal myopathy	2021-08-17	criteria provided, single submitter	clinical testing
All of Us Research Program, National Institutes of Health	RCV001183002	SCV004814364	uncertain significance	Cardiomyopathy	2024-09-16	criteria provided, single submitter	clinical testing	This missense variant replaces alanine with valine at codon 1639 of the MYH7 protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has not been reported in individuals affected with MYH7-related disorders in the literature. This variant has been identified in 1/31384 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.
Ambry Genetics	RCV004984916	SCV005453795	uncertain significance	Cardiovascular phenotype	2024-08-21	criteria provided, single submitter	clinical testing	The p.A1639V variant (also known as c.4916C>T), located in coding exon 32 of the MYH7 gene, results from a C to T substitution at nucleotide position 4916. The alanine at codon 1639 is replaced by valine, an amino acid with similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Based on the available evidence, the clinical significance of this variant remains unclear.
PreventionGenetics, part of Exact Sciences	RCV004541545	SCV004776858	uncertain significance	MYH7-related disorder	2023-12-26	no assertion criteria provided	clinical testing	The MYH7 c.4916C>T variant is predicted to result in the amino acid substitution p.Ala1639Val. This variant was reported in two apparently unaffected individuals from a cohort study of patients with hypertrophic cardiomyopathy (Table S6, Park et al. 2022. PubMed ID: 34542152). This variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence.